Trial Profile
Phase I Study of Pacritinib and Chemotherapy in Patients With Acute Myeloid Leukemia and FLT3 Mutations
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pacritinib (Primary) ; Cytarabine; Daunorubicin; Decitabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 17 May 2019 Results from a pilot phase I study evaluating the toxicity profile, pacritinib pharmacokinetics and preliminary clinical activity of pacritinib administered in combination with cytarabine and daunorubicin or with decitabine in adults with FLT3-ITD+ AML published in the Investigational New Drugs
- 23 Jan 2019 Status changed from suspended to completed.
- 24 Jul 2018 Planned End Date changed from 1 May 2018 to 30 Sep 2018.